Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ophthotech has reported that the first patient has been enrolled in its Phase I clinical trial for the treatment of wet age-related macular degeneration or AMD.
Subscribe to our email newsletter
The Phase I trial will assess the safety and tolerability of E10030, an anti-PDGF aptamer, in combination with an anti-VEGF agent. E10030 is the first of three compounds that Ophthotech is developing to treat AMD. This trial will enroll up to a maximum of 36 patients.
Samir Patel, president and CEO of Ophthotech, said: “We believe E10030 holds great promise for enhancing the visual outcome for patients with AMD.”